Why the study?
Congestive heart failure involves profound cardiac metabolic remodelling in lipid utilization, and the synergistic mechanisms of the traditional Chinese medicines Hedan Pill and Shexiang Baoxin Pill in congestive heart failure remain unclear.
Does adding Hedan Pill or Shexiang Baoxin Pill to sacubitril/valsartan improve cardiac function and lipid metabolism via the PPARα-CPT1A axis in an ApoE-/- mouse model of congestive heart failure?
Does adding Hedan Pill or Shexiang Baoxin Pill to sacubitril/valsartan improve cardiac function and lipid metabolism via the PPARα-CPT1A axis in an ApoE-/- mouse model of congestive heart failure?
This preclinical study demonstrates that combining Hedan Pill or Shexiang Baoxin Pill with sacubitril/valsartan synergistically improves lipid metabolism and attenuates myocardial injury via the PPARα–CPT1A–SREBP-1c axis in experimental cardiometabolic heart failure.
Answers are grounded in this paper and cite their sources.
Should not change practice in heart failure; hypothesis-generating for adjunctive traditional Chinese medicine effects on lipids in cardiometabolic models.
Congestive heart failure (CHF) is associated with profound cardiac metabolic remodelling, particularly in lipid utilization. While Hedan Pill and Shexiang Baoxin Pill are traditional Chinese medicines with cardiovascular benefits, their synergistic mechanisms in CHF remain unclear. Network pharmacology and molecular docking were combined with in vivo validation using ApoE −/− mice fed a high‐fat diet and subjected to isoproterenol (ISO) treatment. Animals were allocated to seven groups: control, model, Entresto, Hedan Pill, Shexiang Baoxin Pill, Entresto + Hedan Pill, and Entresto + Shexiang Baoxin Pill. Cardiac function, serum lipids, myocardial histopathology, and protein expression of peroxisome proliferator‐activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and sterol regulatory element‐binding protein 1c (SREBP‐1c) were assessed. Network analysis indicated convergence on the PPARα–lipid metabolism pathway, with strong binding affinities between several active compounds and PPARα (≤ −7.0 kcal mol −1 ). In vivo, Hedan Pill or ShexiangBaoxin Pill alone improved ejection fraction, reduced triglycerides, and alleviated fibrosis and lipid deposition. Compared with Entresto alone, both combination regimens further reduced serum triglycerides and LDL‐C, whereas ejection fraction did not differ significantly. Mechanistically, both agents upregulated myocardial PPARα and CPT1A while suppressing SREBP‐1c. Hedan Pill and Shexiang Baoxin Pill synergistically improve cardiac lipid metabolic homeostasis through the PPARα–CPT1A axis, thereby protecting against CHF‐induced myocardial injury. These findings provide physiological and mechanistic evidence supporting their translational potential as complementary interventions in CHF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Experimental congestive heart failure with dyslipidemia (n=48). Hedan Pill (1.5 g/kg) or Shexiang Baoxin Pill (18 mg/kg), alone or combined with sacubitril/valsartan (Entresto, 30 mg/kg) vs. Untreated high-fat diet + isoproterenol CHF model group, standard diet control group, and sacubitril/valsartan (30 mg/kg) monotherapy group was evaluated on Serum triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels, cardiac function (ejection fraction), and myocardial PPARα/CPT1A/SREBP-1c protein expression (p=<0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: